Already rolling in diabetes and obesity, Eli Lilly touts tirzepatide's midstage MASH win
Fierce Pharma
FEBRUARY 6, 2024
In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.< | Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease with a massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect.
Let's personalize your content